Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo

Clinical and Experimental Immunology

Volumn 107, Issue 1, 1997, Pages 50-56

  Aukrust, P ^a,b   Muller F ^a   Nordoy I ^a   Haug, C J ^a   Froland S S ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Intravenous immunoglobulin; Lymphocyte proliferation; Neopterin; Reactive oxygen species; Soluble CD8 antigen

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOREGULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031032706     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-904.x     Document Type: Article

References (36)

1. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-16.
2. Aukrust P, Frøland SS, Liabakk N-B, Müller F, Nordøy I, Haug C, Espevik T. Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43.
3. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180-6.
4. van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12:325-34.
5. Andersson U, Björk L, Skansén-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21-42.
6. Jungi TW, Brcic M, Kurnert P, Spycher MO, Li F, Nydegger UE. Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 1990; 82:163-9.
7. White WB, Desbonnet CR, Ballow M. Immunoregulatory effects of intravenous immune globulin therapy in common variable immunodeficiency. Am J Med 1987; 83:431-6.
8. Macey MG, Newland AC, CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol 1990;76:513-20.
9. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effects of intravenous immunoglobulin (IVIG) on peripheral blood B, NK and T cell subpopulations in women with recurrent spontaneous abortion: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994; 71:309-14.
10. Ling Z-D, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS. Intravenous immunoglobulin induces interferon-γ and interleukin-6 in vivo. J Clin Immunol 1993; 13:302-9.
11. WHO Scientific Group Report. Primary immunodeficiency. Clin Exp Immunol 1995; 97(Suppl. 1):1-24.
12. Spickett GP, Misbah SA, Chapel HM. Primary antibody deficiency in adults. Lancet 1991; 337:281-4.
13. Aukrust P, Frøland SS, Müller F. Raised serum neopterin levels in patient with primary hypogammaglobulinaemia: correlation to other immunological parameters and to clinical and histological features. Clin Exp Immunol 1992; 89:211-6.
14. + lymphocytes. Clin Immunol Immunopathol 1994; 70:217-24.
15. Müller F, Rollag H, Gaudernack G, Frøland SS. Impaired in vitro survival of monocytes from patients with HIV infection. Clin Exp Immunol 1990; 81:25-30.
16. Gaudernack G, Lundin KE. Rapid immunomagnetic phenotyping of cells. J Immunogenet 1989; 16:169-75.
17. Aukrust P, Müller F, Frøland SS. Enhanced generation of reactive oxygen species in monocytes from patients with common variable immunodeficiency. Clin Exp Immunol 1994; 97:232-8.
18. Müller F, Rollag H, Frøland SS. Nitroblue tetrazolium reduction in monocytes and monocyte-derived macrophages. APMIS 1989; 97:490-6.
19. Brinchmann JE, Vandal F, Gaudernack G, Markussen G, Funderud S, Ugelstad J, Thorsby E. Direct immunomagnetic quantification of lymphocyte substes in blood. Clin Exp Immunol 1988; 71:182-6.
20. Huber C, Batchelor JR, Fuchs D et al. Immune-response associated with neopterin production. J Exp Med 1984; 160:310-6.
21. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for cell-mediated immunity. Immunol Today 1988; 9:150-5.
22. Segal AW. The respiratory burst in monocytes and macrophages. In: Zembala M, Asherson G, eds, Human monocytes. London: Academic Press, 1989;89-100.
23. Tomkinson BE, Bown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T-cell activation. J Immunol 1989; 142:2230-6.
24. + cells in HIV-1-infected patients. AIDS 1991; 5:813-9.
25. Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune response in vitro. Scand J Immunol 1993; 38:477-84.
26. Saoudi A, Hurez V, de Kozak Y et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5:1559-67.
27. Arend WP, Leung DYM. IgG induction of IL-1 receptor antagonist by human monocytes. Immunol Rev 1994; 139:71-78.
28. de Souza VR, Carreno M-P, Kaveri SV et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25:1267-73.
29. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today 1991; 12:349-52.
30. Dinarello CA, Thompson RC. Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12:404-10.
31. Andersson UG, Björk L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79:211-6.
32. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of human immunoglobulin: one possible mechanism of the clinical effects of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:6-14.
33. Farber CM, Crusiaux A, Schandené L, van Vooren JP, Goldman M, Dupont E, Tasiaux N. Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency. Clin Immunol Immunopathol 1994; 72:233-6.
34. Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, Cohen IR, Lider O. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. J Clin Invest 1994; 93:600-5.
35. + lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor α system: possible immunopathogenic role of oxidative stress. Blood 1995; 86:1383-91.
36. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992; 119:598-620.